Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Mar;12(1):44-46.
doi: 10.17925/EE.2016.12.01.44. Epub 2016 Mar 15.

New Developments in the Treatment of Neuroendocrine Tumours - RADIANT-4, NETTER-1 and Telotristat Etiprate

Emilia Sbardella  1 , Ashley Grossman  1
Affiliations
Editorial

New Developments in the Treatment of Neuroendocrine Tumours - RADIANT-4, NETTER-1 and Telotristat Etiprate

Emilia Sbardella et al. Eur Endocrinol. 2016 Mar.

Abstract

Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms whose incidence has increased significantly in recent years, and whose optimal management remains controversial. We report the latest innovations in their management, in particular the results of three trials concerning the use of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, in non-functional NETs of lung/ gastrointestinal (GI) origin, the first randomised trial of radiolabelled 177Lu-DOTATATE in patients with mid-gut NETs, and the use of the 5-HT synthesis inhibitor, telotristat etiprate, in patients with the carcinoid syndrome.

Keywords: 177Lu-DOTATATE; 5-HT synthesis inhibitor; Neuroendocrine tumours; everolimus; telotristat etiprate; treatment.

PubMed Disclaimer

References

    1. Modlin I. M., Oberg K., Chun D. C.. et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72. - PubMed
    1. Huguet I., Grossman A. B., O’Toole D.. et al. Changes in the Epidemiology of NETs. Neuroendocrinology. 2015 Epub ahead of print. - PubMed
    1. Ramage J. K., Ahmed A., Ardill J.. et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) Gut. 2012;61:6–32. - PMC - PubMed
    1. Yao J. C., Hassan M., Phan A.. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72. - PubMed
    1. Rinke A., Muller H. H., Schade-Brittinger C.. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63. - PubMed

Publication types